Literature DB >> 19495761

[Mesenchymal uterine tumors. Leiomyomas].

S Lax1.   

Abstract

Leiomyomas are by far the most frequent mesenchymal uterine neoplasms. Leiomyoma variants refer to a particular histological differentiation and growth pattern, respectively. To assess malignancy, an algorithm is used based on the presence or absence of cellular atypia, tumor cell necrosis and mitosis. In addition, vascular invasion is a criterion for malignancy. Ischemic or infarct type necrosis is not considered a criterion for malignancy. The differential diagnosis of leiomyosarcoma includes cellular and mitotically active leiomyoma and leiomyoma with extensive infarct type necrosis (apoplectic leiomyoma). The term smooth muscle tumor of uncertain malignant potential (STUMP) should be reserved for tumors with uncertainty regarding cell type, type of necrosis and mitotic index, as well as for special cases of myxoid and epithelioid smooth muscle neoplasms. Immunohistochemically, the expression of desmin and caldesmon is indicative of smooth muscle tumors, while stromal tumors can express smooth muscle actin and, rarely, desmin in addition to CD10.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19495761     DOI: 10.1007/s00292-009-1160-1

Source DB:  PubMed          Journal:  Pathologe        ISSN: 0172-8113            Impact factor:   1.011


  14 in total

1.  Epithelioid smooth-muscle tumors of the uterus: a clinicopathologic study of 18 patients.

Authors:  R A Prayson; J R Goldblum; W R Hart
Journal:  Am J Surg Pathol       Date:  1997-04       Impact factor: 6.394

Review 2.  Smooth muscle tumors of the uterus: a practical approach.

Authors:  Gemma Toledo; Esther Oliva
Journal:  Arch Pathol Lab Med       Date:  2008-04       Impact factor: 5.534

3.  Prognostically favorable "mitotically active" smooth-muscle tumors of the uterus. A clinicopathologic study of ten cases.

Authors:  T Perrone; L P Dehner
Journal:  Am J Surg Pathol       Date:  1988-01       Impact factor: 6.394

4.  Mesenchymal tumors of the uterus. VI. Epithelioid smooth muscle tumors including leiomyoblastoma and clear-cell leiomyoma: a clinical and pathologic analysis of 26 cases.

Authors:  R J Kurman; H J Norris
Journal:  Cancer       Date:  1976-04       Impact factor: 6.860

5.  Problematic uterine smooth muscle neoplasms. A clinicopathologic study of 213 cases.

Authors:  S W Bell; R L Kempson; M R Hendrickson
Journal:  Am J Surg Pathol       Date:  1994-06       Impact factor: 6.394

6.  Molecular pathogenesis of uterine smooth muscle tumors from transcriptional profiling.

Authors:  Bradley J Quade; Tao-Yeuan Wang; Kris Sornberger; Paola Dal Cin; George L Mutter; Cynthia C Morton
Journal:  Genes Chromosomes Cancer       Date:  2004-06       Impact factor: 5.006

7.  Tissue microarray immunohistochemical expression of estrogen, progesterone, and androgen receptors in uterine leiomyomata and leiomyosarcoma.

Authors:  Mario M Leitao; Robert A Soslow; Daisuke Nonaka; Adam B Olshen; Carol Aghajanian; Paul Sabbatini; Jakob Dupont; Martee Hensley; Yukio Sonoda; Richard R Barakat; Sibyl Anderson
Journal:  Cancer       Date:  2004-09-15       Impact factor: 6.860

8.  Immunohistochemical analysis of p16, p53, and Ki-67 expression in uterine smooth muscle tumors.

Authors:  Longwen Chen; Bin Yang
Journal:  Int J Gynecol Pathol       Date:  2008-07       Impact factor: 2.762

9.  Hemorrhagic cellular leiomyomas ("apoplectic leiomyoma") of the uterus associated with pregnancy and oral contraceptives.

Authors:  H J Norris; G D Hilliard; N S Irey
Journal:  Int J Gynecol Pathol       Date:  1988       Impact factor: 2.762

10.  Cellular benign mesenchymal tumors of the uterus. A comparative morphologic and immunohistochemical analysis of 33 highly cellular leiomyomas and six endometrial stromal nodules, two frequently confused tumors.

Authors:  E Oliva; R H Young; P B Clement; A K Bhan; R E Scully
Journal:  Am J Surg Pathol       Date:  1995-07       Impact factor: 6.394

View more
  1 in total

Review 1.  [Mesenchymal and mixed uterine tumors : Current overview and practical aspects].

Authors:  S F Lax
Journal:  Pathologe       Date:  2019-02       Impact factor: 1.011

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.